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Abstract
Background: Aplastic anemia (AA) is characterized by pancytopenia and bone marrow hypoplasia, which results
from immune-mediated hematopoiesis suppression. Understanding the pathophysiology of the immune system,
particularly T cells immunity, has led to improved AA treatment over the past decades. However, primary and
secondary failure after immunosuppressive therapy is frequent. Thus, knowledge of the immune mechanisms
leading to AA is crucial to fundamentally understand the disease.
Findings: To elucidate the T cell receptor (TCR) signal transduction features in AA, the expression levels of CD3g, δ,
ε and ζ chain and FcεRIg genes, which are involved in TCR signal transduction, and the negative correlation of the
expression levels between the CD3ζ and FcεRIg genes in T cells from peripheral blood mononuclear cells (PBMCs)
were analyzed. Real-time RT-PCR using the SYBR Green method was used to detect the expression level of these
genes in PBMCs from 18 patients with AA and 14 healthy individuals. The b2microglobulin gene (b2M) was used
as an endogenous reference. The expression levels of the CD3g, CD3δ, CD3ε and CD3ζ genes in patients with AA
were significantly increased compared to a healthy control group, whereas the FcεRIg gene expression level was
significantly decreased in patients with AA in comparison with the healthy control group. Moreover, the negative
correlation of the expression levels between the CD3ζ and FcεRIg genes was lost.
Conclusions: To our knowledge, this is the first report of the CD3g, CD3δ, CD3ε, CD3ζ and FcεRIg gene expression
in patients with AA. The abnormally expressed TCR signaling related genes may relate to T cells dysfunction in AA.
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Introduction
Aplastic anemia (AA) is a potentially fatal bone marrow
failure disorder that is characterized by pancytopenia and
bone marrow hypoplasia. In most cases, AA behaves as
an immune-mediated disease [1]. Immunosuppression is
a key treatment strategy for patients who are not suitable
bone marrow transplant (BMT) candidates due to age or
the lack of a suitable donor. Immunosuppression with
antithymocyte globulins and cyclosporine is effective for
restoring blood cell production in the majority of patients
[2,3]. The thought that T cells play a major role in the
pathophysiology of AA became evident in the late 1970s
with the finding that marrow and peripheral blood lym-
phocytes from patients with AA were able to suppress
hematopoiesis in vitro. Subsequently, activated CD8
+
T cells were identified as the lymphocyte subset that
inhibited hematopoiesis in AA patients [4]. Further stu-
dies have indicated that the mechanism includes Fas-
induced apoptosis [5] and the release of several inhibitory
cytokines including g-interferon (IFN-g), tumor necrosis
factor-a (TNF-a) and transforming growth factor-b
(TGF-b) [6-8]. Subsequent studies have demonstrated
that oligoclonal expanded cytotoxic T cells target hema-
topoietic stem and progenitor cells [1]. All of these find-
ings suggest that the molecular basis of the aberrant
immune response and deficiencies in hematopoietic cells
is T cells activation pathway dysregulation [9]. * Correspondence: yangqiuli@hotmail.com
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tion about the quantity and quality of antigen engage-
ment is relayed to the intracellular signal transduction
machinery. The TCR lacks a significant intracellular
domain. Instead, it associates with CD3 molecules, which
contain intracellular signaling domains that couple the
TCR/CD3 complex to downstream signaling machinery.
The earliest TCR signaling events involve the transfer of
information from the antigen-binding TCR subunit to
the CD3 signaling subunits in the TCR/CD3 complex
[10]. The Fc epsion receptor type Ig (FcεRIg)c h a i ni sa
member of the CD3ζ chain protein family, and it is a
component of the high-affinity IgE receptor FcεRI. There
is evidence that the FcεRIg chain can replace a function-
ally deficient CD3ζ chain and facilitate TCR/CD3 com-
plex-mediated signaling [11,12].
Growing evidence has shown that AA is a type of autoim-
mune disease that involves a T cell attack against hemato-
poietic progenitor cells [13]. Oligoclonal T cells expansion
was detected in autoimmune diseases such as systemic
lupus erythematosus (SLE), rheumatoid arthritis and multi-
ple sclerosis [14-17]. The TCR/CD3 signaling complex
appears to be down-regulated by mutations/polymorphisms
in autoimmune diseases, chronic inflammation and malig-
nant tumors, which are thought to be related to T cells
immunodeficiency [18,19].
Antigen-specific T cells play a central role in immune
and inflammatory responses. An appropriate immune
response by these cells depends on the careful regulation
of their activation. However, little is known about the
expression pattern of the CD3 complex and FcεRIg genes
in AA patients. We concluded that analysis of these
g e n e si nA Ap a t i e n t sd u r i n gt heir initial presentation
may serve to identify the abnormal immune characteris-
tics of AA.
Methods
Samples
The AA group consisted of 18 patients with newly diag-
nosed AA (12 males and 6 females; median age: 21 years,
range: 8-73 years). Two of the cases were collected after
immunosuppression treatment (ATG + CsA) at different
time points (i.e., 1, 3 or 4 months). The information and
clinical data of patients were described in Table 1 and 2.
Fourteen healthy individuals (9 males and 5 females;
median age: 24.5 years, range: 12-65 years) served as the
control group. The AA diagnosis was established by bone
marrow biopsy and peripheral blood counts. All of the
procedures were performed according to the guidelines
of the Medical Ethics committee of the health bureau of
the Guangdong Province of China. Peripheral blood
mononuclear cell (PBMC) isolation, RNA extraction and
cDNA synthesis were performed according to the manu-
facturer’s instructions.
Real-time relative quantitative PCR for CD3gδεζ and FcεRIg
genes
Real-time PCR using the SYBR Green I method was
used to examine the CD3g, δ, ε, ζ and FcεRIg gene
expression levels using cDNA obtained from the PBMCs
of the 18 patients. The primer sequences and PCR con-
ditions have been previously described [20]. Briefly, the
Table 1 Clinical data of AA patient
Case number Age (years) Sex Hb(g/L) ANC (10
9/L) PLT (10
9/L)
1 10 Female 60 0.1 69
2 17 Male 112 1.2 39
3 24 Male 40 0.3 42
4 12 Male 69 0.8 24
5 14 Female 55 0.4 29
6 28 Male 87 0.8 90
7 27 Male 67 0.3 45
8 19 Male 91 0.7 29
9 73 Male 59 1.1 94
10 15 Female 81 0.4 63
11 8 Female 65 0.4 12
12 19 Female 74 0.1 52
13 18 Male 71 0.1 45
14 48 Male 40 0.1 24
15 57 Male 83 0.3 30
16 31 Male 47 0.5 21
17 35 Female 63 0.1 20
18 26 Male 108 0.2 12
Note: Hb:haemoglobin; ANC: absolute neutrophil count PLT: platelet
Li et al. Journal of Hematology & Oncology 2012, 5:6
http://www.jhoonline.org/content/5/1/6
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μl containing approximately 1 μl cDNA, 0.5 μMo fe a c h
primer pair, and 11.25 μl 2.5 × RealMasterMix (Tiangen,
Beijing). After an initial denaturation at 95°C for 2 min,
45 cycles consisting of the following procedure was per-
formed using an MJ Research DNA Engine Opticon 2
PCR cycler (BIO-RAD, Hercules, CA, USA): 15 s at 95°
C; 1 min at 58.9°C for b2M and CD3g, 60°C for CD3ζ
and FcεRIg,6 0 . 8 ° Cf o rC D 3 δ, and 62°C for CD3ε;a n d1
s at 82°C for plate reading. The 2
(-ΔCT) method was
used to analyze the results of the genes of interest rela-
tive to an internal control gene [21].
Statistical analysis
An independent-samples t test was performed to com-
pare the mean of each gene expression level between
the patients with AA and the control groups. Pearson
correlation and linear regression analyses were used to
estimate the correlation between the CD3ζ and FcεRIg
gene expression levels from the different groups. A P <
0.05 was considered statistically significant.
Results and discussion
The gene expression levels of CD3g,C D 3 δ,C D 3 ε,C D 3 ζ
and FcεRIg in cDNA obtained from the PBMCs of 18
patients with AA before treatment and 14 healthy
individuals were quantitatively assessed by real-time
PCR using the SYBR Green I method.
All five genes were detected in every sample. Signifi-
cantly higher expression levels of CD3g (17.84 ± 20.97,
p =0 . 0 1 5 ) ,C D 3 δ (3.24 ± 2.61, p =0 . 0 0 2 ) ,C D 3 ε (15.73 ±
11.44, p =0 . 0 0 0 ) ,a n dC D 3 ζ (5.65 ± 3.51, p = 0.000) were
observed in patients with AA compared to the healthy
controls (CD3g (4.43 ± 2.67), CD3δ (1.02 ± 0.69), CD3ε
(3.36 ± 2.09), and CD3ζ (1.83 ± 1.21) for the healthy con-
trols; Figure 1). In contrast, significantly lower FcεRIg
expression levels (17.63 ± 9.95) were found in the AA
group compared to the healthy group (30.55 ± 23.21, p =
0.041).
The expression level of all five genes was compared in
two patients with AA before and after treatment. The
expression levels of the CD3g,C D 3 δ,C D 3 ε and CD3ζ
genes decreased, and the FcεRIg expression level of
increased after treatment (Figure 2A, B). The CD3g expres-
sion level decreased from 34.03 to 1.31, the CD3δ expres-
sion level decreased from 3.36 to 0.52, the CD3ε
expression level decreased from 45.06 to 2.96, the CD3ζ
expression level decreased from 10.96 to 0.86, and the
FcεRIg expression level increased from 5.97 to 107.55 in
the 3 months after treatment in 1 case (Figure 2A). The
expression levels of CD3δ,C D 3 ε and CD3ζ returned to the
normal range compared to the healthy group, whereas the
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Figure 1 The relative gene expression levels of CD3g, CD3δ, CD3ε, CD3ζ and FcεRIg in PBMCs from the AA and healthy groups.
Table 2 Clinical data of follow-up patients
Case number Time Hb (g/L) ANC (10
9/L) PLT (10
9/L)
1 Before treatment
4 months after treatment
60
66
0.1
0.6
69
45
2 Before treatment
1 months after treatment
112
119
1.2
1.1
39
43
3 months after treatment 124 1.6 47
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Page 3 of 7CD3g and FcεRIg expression levels did not. In another case,
the CD3g expression level decreased from 10.57 to 0.82,
the CD3δ expression level decreased from 3.95 to 0.63, the
CD3ε expression level decreased from 19.14 to 2.23, the
CD3ζ expression level decreased from 5.91 to 0.54, and the
FcεRIg expression level increased from 30.89 to 36.60 in
the 4 months after treatment (Figure 2B). With the excep-
tion of the expression levels of CD3g and CD3ζ,w h i c h
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Figure 2 The relative gene expression levels of CD3g, CD3δ, CD3ε, CD3ζ and FcεRIg in the PBMCs from 2 patients after treatment.
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the other genes returned to normal.
A significant negative correlation between the CD3ζ
and FcεRIg gene expression levels was found in the
healthy group (r = -0.535, p = 0.049; Figure 3A), while
there was no significant correlation between the expres-
sion levels of the genes in the AA group (r = 0.252, p =
0. 313; Figure 3B).
The TCR has a short intracellular sequence that lacks
signaling capacity, and the CD3 molecule contains
immunoreceptor tyrosine-based activation motifs
(ITAMs), which couple the TCR to the signal transduc-
tion mechanism. In mature T-lymphocytes, the TCR/
CD3 complex can essentially trigger all adaptive immune
responses [22,23]. TCR signal transduction is mediated
by the ITAMs. A total of 10 ITAMs are distributed in the
TCR/CD3 complex in two distinct signaling modules
termed the TCRζζ and CD3gε/δε [24,25]. Although the
TCRζζ ITAM plays a central role in TCR signal transmis-
sion, the CD3gε/δε ITAM module can provide normal
TCR signal transmission in the absence of a TCRζζ
ITAM motif [26]. To gain more insight into TCR signal
transduction, which is important for T cells activation,
we analyzed the expression level of all four CD3 genes
(i.e., CD3g, CD3δ, CD3ε and CD3ζ) and the CD3ζ-related
FcεRIg gene in PBMCs from patients with AA.
In contrast with recent studies that have revealed
decreased CD3ζ chain protein and mRNA levels in most
patients with AA, their results were derived from only five
newly diagnosed patients with AA and patients (25 cases)
in remission or relapse [27]. In this study, we analyzed the
expression pattern of all of the CD3 genes, and the data
indicated that not only the CD3ζ,b u ta l s ot h eC D 3 g,
CD3δ and CD3ε expression levels were significantly
increased in comparison with those in the healthy group.
The results suggested that there may be a different T cells
signaling pathway activation disorder in AA. Like many
other cell surface receptors, TCR/CD3 complexes are
constitutively internalized and recycled back to cell sur-
face. This downmodulation of TCR/CD3 at the cell sur-
face prevents sustained signalling in T-APC conjugates
and modulates the responsiveness of T cells to further
antigenic stimulation [28].U p - r e g u l a t i o no fC D 3g e n e
expression in AA suggests that T cells may be in sustained
signaling stimulation in the periphery that leads to inap-
propriate T cell activation.
Unlike the CD3ζ chain, which mediates signaling
through ZAP-70, FcεRIg mediates signaling by associat-
ing with the phosphorylated protein kinase Syk [12,29]. It
has been reported that the Syk kinase is 100-fold more
potent than Zap-70 [30], and it is preferentially recruited
to the FcεRIg [31]. Krishnan et al. have found a physiolo-
gical switch through which primary resting CD4
+T cells
transduce signals to the classical TCR/CD3ε/CD3ζ/Zap-
70 complex, and effector CD4
+T cells express and trans-
duce signals through an alternate TCR signaling complex
that excludes CD3ζ/Zap-70 and contains CD3ε,t h e
FcεRIg subunit and the proximal Syk kinase [32]. It is
interesting that this physiological switch in the TCR/CD3
signaling complex is not observed in CD8
+ T cells [33].
The TCR signaling alterations identified in our study sug-
gest that the reduction in FcεRIg expression in AA was
unable to contribute to TCR signal transduction in a
similar manner as the conserved functional ITAM motif.
In this study, we first analyzed the FcεRIg gene expres-
sion level and its correlation with CD3ζ gene expression
in patients with AA; the FcεRIg expression level was
down-regulated and did not correlate with the CD3ζ
expression level. These findings are in contrast to the
immune status in SLE [12], where a lower CD3ζ expres-
sion is associated with a higher FcεRIg expression level.
These data suggest that the different dysregulated T
cells activation pathways involved in AA may be more
complicated, and AA is unlikely to be a typical autoim-
mune disease T cells disorder. We were unable to follow
up with the clinical outcome of all the patients who
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Figure 3 Correlation between the CD3ζ and FcεRIg gene expression levels in PBMCs of the AA treatment and healthy groups (A: CD3ζ
vs. FcεRIg in the healthy group, the significant negative correlation is indicated; B: CD3ζ vs. FcεRIg in the AA group)
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Page 5 of 7were selected for this study. We monitored the change
in the CD3g,C D 3 δ,C D 3 ε,C D 3 ζ and FcεRIg gene
expression levels in 2 patients with AA who were in
remission. All of the gene expression patterns changed
relative to the normal level. These data suggest that the
expression of these genes is disease status dependent.
However, a limited number of patients (2 cases) were
examined in this follow-up study; thus, this hypothesis
should be confirmed in future studies with larger sample
sizes.
Conclusions
To our knowledge, this study is the first attempt to pro-
v i d eag e n ee x p r e s s i o np r o f i l eo ft h eC D 3 g, δ, ε,a n dζ
chains and the related FcεRIg gene in PBMCs from
patients with AA. Taken together, the increased T cells
activation, along with the abnormally immunological
molecules may be an AA feature. Abnormal T cells activa-
tion in AA creates a cellular imbalance between immunity
and tolerance, leading to immune system-mediated bone
marrow failure.
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